SCHEMBL20566784

SCHEMBL20566784

Cc1c(CN2CCC3(CCN(C(=O)n4ccc(C(=O)O)n4)CC3)C2)cccc1C(F)(F)F

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FAAH O00519 15/20 0.71
MGLL Q99685 9/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20566943 0.90 FAAH (0.75) FAAHMGLL
SCHEMBL25487817 0.88 MGLL (0.71) FAAHMGLL
SCHEMBL25644308 0.87 FAAH (0.54) FAAHMGLL
SCHEMBL25488153 0.86 MGLL (0.71) FAAHMGLL
SCHEMBL20567129 0.85 FAAH (0.64) FAAHMGLL
SCHEMBL20566274 0.84 FAAH (0.73) FAAHMGLL
SCHEMBL30420850 0.84 FAAH (0.73) FAAHMGLL
SCHEMBL20567193 0.84 FAAH (0.70) FAAHMGLL
SCHEMBL20920407 0.83 FAAH (0.74) FAAHMGLL
SCHEMBL25488151 0.83 MGLL (0.74) FAAHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
EP-3630744-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2023-01-25 EP disclosed
US-20220031676-A1 METHODS OF TREATING DISEASE WITH MAGL INHIBITORS H. LUNDBECK A/S (DK) 2022-02-03 US disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 US disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 US disclosed
WO-2020112905-A1 METHODS OF TREATING DISEASE WITH MAGL INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2020-06-04 WO disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL FAAH 33/4885MGLL 1/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL FAAH 33/4885MGLL 1/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL FAAH 32/4885MGLL 1/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL FAAH 33/4885MGLL 1/4885
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL FAAH 33/4885MGLL 1/4885
US-20220031676-A1 METHODS OF TREATING DISEASE WITH MAGL INHIBITORS MGLL, LIPA, PNLIP FAAH 67/4885MGLL 1/4885
US-11655217-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL FAAH 32/4885MGLL 1/4885
US-10927105-B1 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL FAAH 33/4885MGLL 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.